

Estimating a preference-based single index from the Asthma Quality of Life Questionnaire (AQLQ)

Yang, Y; Tsuchiya, A; Brazier, J and Young, T

2007

Online at http://mpra.ub.uni-muenchen.de/29804/MPRA Paper No. 29804, posted 23. March 2011 / 15:35



HEDS Discussion Paper 07/02

Disclaimer:

This is a Discussion Paper produced and published by the Health Economics and Decision Science (HEDS) Section at the School of Health and Related Research (ScHARR), University of Sheffield. HEDS Discussion Papers are intended to provide information and encourage discussion on a topic in advance of formal publication. They represent only the views of the authors, and do not necessarily reflect the views or approval of the sponsors.

White Rose Repository URL for this paper: http://eprints.whiterose.ac.uk/10917/

Once a version of Discussion Paper content is published in a peer-reviewed journal, this typically supersedes the Discussion Paper and readers are invited to cite the published version in preference to the original version.

Published paper

None.

White Rose Research Online eprints@whiterose.ac.uk





ScHARR

Health Economics and Decision Science Discussion Paper Series

No. 07/02

Estimating a preference-based single index from the Asthma Quality of Life Questionnaire (AQLQ)

Yaling Yang, Aki Tsuchiya, John E. Brazier, Tracey A. Young

Corresponding author: Yaling Yang (cmp04yy@sheffield.ac.uk)

HEDS, ScHARR, University of Sheffield

Regent Court, 30 Regent Street, Sheffield, UK, S1 4DA

Tel: +44 (0) 114 2226386 Fax: +44 (0) 114 2224095 Abstract: This paper presents a study to estimate a preference-based single index from the Asthma Quality of Life Questionnaire (AQLQ). Based on the AQL-5D which is a health classification system directly derived from AQLQ, 98 health states was valued by a sample of 307 members of the UK general population. Models were estimated to predict all possible 3125 health states defined by the AQL-5D and compared using a set of criteria. The mean model of main effects was recommended of preferable prediction ability and logically consistent and significant coefficients for levels of dimensions. However, there are concerns over condition-specific valuation issues, such as presenting asthma information to general public and the choice of condition specific full health as the upper anchor for TTO valuation.

Key words: AQL-5D, health state valuation, condition-specific, Time-trade-off, asthma

Acknowledgements

This study is funded by Novartis. John Brazier is funded by the Medical Research Council Health Services Research Collaboration. We are grateful to all the survey participants; the COGENT project at the University of Newcastle for allowing us to use their dataset; and to Asthma UK and the Wellington Asthma Research for their permission to use their video clips on asthma. The usual disclaimer applies.

Introduction

Cost-effectiveness analysis has been widely used as a tool to support decision making on health resource allocation in the last decade, especially with establishment of government agencies such as the National Institute for Health and Clinical Excellence (NICE) in the UK and similar agencies around the world (ISPOR, 2006). A cost-effectiveness study may employ Quality Adjusted Life Years (QALYs) as the outcome measure to enable direct comparisons across different health interventions or different medical conditions.

The QALY combines quality of life (expressed in terms of a "utility" score) and length of life (in years) into a single index. The utility score reflects the quality of life of a given health state and is elicited through valuation exercises, such as the Standard Gamble, Time Trade-off (TTO), or the Visual Analogue Scale (VAS). The scores lie on a scale of 0 to 1, where 0 is equivalent to dead and 1 equivalent to perfect health. Economic evaluations of health care technologies can either carry out their own valuation studies of the health states relevant to the given research project, or they can use "off the shelf" generic preference-based instruments. These instruments have pre-scored health classification system and are able to estimate utility scores for all possible health states: examples include EQ-5D (Dolan, 1997), Health Utility Index (HUI; Feeny et al, 2002), Quality of Well-being Scale (QWB; Anderson et al, 1989) and SF-6D (Brazier et al, 2002). Such "off the shelf instruments" have been widely used in cost-effectiveness studies not only because of their convenience, but also because they improve comparability across studies.

A clinical trial often includes disease-specific quality of life instruments to capture clinical efficacy, and increasingly, one of the generic preference-based instruments in order to derive QALYs and to calculate cost effectiveness. Generic preference-based instruments typically cover dimensions of health such as mobility, pain, activity limitation, and anxiety or depression. However, for certain medical conditions, the set of dimensions covered by generic measures may not be relevant, or even where relevant, they have been found to insensitive (Guyatt GH, et al, 1999; Jenkinson C, et al, 1997) by missing 'small but important changes' or requiring a larger sample size for some specific medical conditions. At the same time, many clinical trials currently exclude generic measures, either due to concerns about patient burden or because they are not regarded as appropriate by those designing the trial. This disadvantage evoked the debate on roles of generic and condition-specific health related measures in health care decision making, (Dowie J, 2002; Feeny D, 2002; Guyatt G; Brazier J, 2002).

One way to improve the sensitivity of generic preference-based measures is to broaden their coverage to include dimensions relevant to the condition being considered (a condition specific 'add-on'). While this approach is worth exploring, another approach is to obtain preference weights for a condition specific descriptive system. This has the advantage that it ensures that the health state utility scores used in economic evaluation better reflect the impact of the medical condition; and secondly it makes better use of the condition-specific measures where generic ones have been excluded. Several studies have been undertaken to obtain health state utility values for condition-specific instruments, such as the multi-attribute Rhinitis Symptom Utility Index (Revicki et al, 1998), the Asthma-Symptom

Utility Index (ASUI) (Revicki et al, 1998), the International Index of Erectile Function (Stolk et al, 2003), health states related to erectile dysfunction (Torrance et al, 2004) and Urinary Incontinence (Brazier et al, 2005).

There has been little written on the methods for developing a preference-based measure from a condition specific measure. The study reported in this paper was undertaken to develop a preference-based single index from an asthma-specific instrument.

The Asthma Quality of Life Questionnaire (AQLQ) has been designed to assess health related quality of life in patients with asthma (Juniper et al, 1993; also see Juniper et al, 1999). It has been used in more than 170 papers quoted by Medline. However, the AQLQ cannot be directly used in economic evaluation in its current form because it does not incorporate preference information.

To derive a preference-based single index measure from the AQLQ, we used a methodology successfully used on the SF-36 by Brazier et al (2002) to generate the SF-6D. The first stage is to derive a reduced health state classification system from the AQLQ that is amenable to valuation exercises using a preference elicitation technique. The second stage is a valuation survey of a selection of states defined by this reduced classification system, by a sample of the UK general population. The third stage is to estimate a range of econometric models for predicting the health state values for all states defined by the new classification system, which in turn will enable the calculation of health state utility values for calculating QALYs based on AQLQ data.

This paper concentrates on the valuation survey and the econometric modelling. For the derivation of the reduced classification system, see Young et al (2005).

The next section describes the AQLQ in more detail. This is followed by a brief description of the reduced classification system used in the valuation survey. Section 3 describes the methods involving in the valuation survey and modelling. Section 4 presents the results of the study including the survey and the models. The final section discusses the results and then use of condition specific preference-based measures in informing resource allocation

1. The AQLQ and the reduced classification system

The AQLQ consists of 32 items with 7 levels each, covering 4 dimensions: symptoms (12 items), activity limitations (11 items), emotional function (5 items) and environmental stimuli (4 items). Table 1 shows the 32 items in the AQLQ.

The original AQLQ is too large to be amenable to valuation. Therefore, based on the application of Rasch analysis and conventional psychometric tests, the AQLQ has been reduced to a 5- dimension health state classification system which we call AQL-5D (see Table 2). The dimensions are: concern about asthma, shortness of breath, weather and pollution stimuli, sleep impact and activity limitations. These dimensions are selected directly from the original AQLQ. Each dimension has 5 levels of severity with level 1 denoting no problem and level 5 indicating extreme problem. All AQLQ health states which contain those five items can be mapped on to the newly defined AQL-5D.

2. Methods

2.1 Valuation survey

The aim of the valuation survey is to elicit preference values from the general public for a sample of health states defined by the AQL-5D. The key methodological issues are the selection of health state sample to be valued, sampling of respondents and overall size of the sample, effective way of presenting asthma disease information to general public, and the technique for eliciting preferences.

2.1.1 Selection of health states

The selection of health states was determined by the specification of the model to be estimated. In this study, 98 health states were selected out of the 3125 possible health states defined by the classification. The selection was on the basis of a balanced design, which ensured that any dimension-level (level λ of dimension δ) had an equal chance of being combined with all levels of the other dimensions. These 98 states were stratified into severity groups based on their total level score across the dimensions (simply the sum of the levels), and then randomly allocated into 14 blocks, so that each block has 7 health states. This procedure ensured that each respondent, who were allocated one of the 14 blocks, received a set of states balanced in terms of severity and that each state is valued the same number of times apart from the worst possible state, or the 'pits' state, which is valued by all respondents.

2.1.2. Respondents

An important methodological issue is whether to sample a group of patients or use a sample of the general population (Drummond et al, 1997). However, health policy bodies such as NICE have recommended using general public values. It was decided to elicit the preference values of general public although this instrument is a condition specific questionnaire.

The respondents are members of the general population randomly selected using the electoral register of names and address from within South Yorkshire, UK. Based on previous experience, we decided to interview a sample of 300 participants providing valuations for 98 health states, which were deemed sufficient to estimate a reliable additive model.

2.1.3 Pilot study on presentation of asthma information

Given that it might be a problem for members of the general public to imagine what it is like to live with asthma, two different ways in which to present information on asthma were piloted on 100 respondents selected in the same way though not included in the main survey. The first presentation was based on around 180 words of verbal information printed on a card (taken from the British Thoracic Society website, see Appendix 1), and the other was based on two brief video clips (provided by Asthma UK, and Wellington Asthma Research) showing the biological mechanism of asthma and patients with asthma symptoms.

Interviews were undertaken in the same way as in the main valuation survey (see 2.1.5) with one "block" containing eight health states. In order to choose one block of health states using in the pilot survey, an assumption of logical consistency must be taken: for any pair of health states, people should give better rank or higher utility value to state A than for B, if A is logically better on at least one dimension and no worse on any other dimension; if not, logical consistency is violated. For any block of with eight health states, there are total twenty-eight opportunities of pair-wise comparisons but not all of them can be used to test logical consistency. The block of health states with the largest potential to violate logical consistency were chosen for the pilot study. The effects of different ways to present asthma information were examined by comparing the time taken for interview, respondents' understanding for the ranking and TTO tasks, violation of strong consistency in the ranking task, and Standard Deviation (SD) of mean TTO values for each health state valued (with the narrower SD the better). The results were used to decide which method to use in the main survey.

A sample of 99 members of the public was interviewed in the pilot survey. The respondents of the verbal information group and the video clip group were comparable in terms of age, gender, education status. However, due to small sample size, unbalance existed as the verbal group was relatively less healthy comparing to video group, with more asthma patients (24/50 comparing to 10/49) and higher self-reported EQ-5D levels. The two groups of respondents had similar results in terms of time taken for the interview, respondents' understanding of the ranking and TTO tasks, violation of consistency in the ranking task. There was no obvious difference between the standard deviations of the mean TTO values

for each health state valued by those two groups. Given that there was no apparent effect on respondents' understanding on asthma information based on these two methods of presenting information or the responses they gave, the simpler method of verbal presentation was chosen for the main survey.

2.1.4 Preference elicitation task

The time trade off (TTO) technique was chosen for eliciting preference values, which asks respondents to trade off between length of life and quality of life. This survey used the TTO-prop method developed by the York Measurement and Valuation Health Group, which uses a 'time board' as a visual aid (Gudex, 1994). This version of TTO was selected because it has been shown to be more reliable than a non props version (Dolan et al, 1996). Furthermore, it has been used to value the EQ-5D.

2.1.5 Interviews

Trained interviewers visited and interviewed respondents at their home during April, 2005.

The interviews consisted of five stages:

- 1. Self-reported health in EQ-5D.
- 2. Part A: self-reported health in AQL-5D for those respondents who replied they have asthma;

Part B: fill in the AQL-5D, imagining that they had asthma, for those respondents who replied they do not have asthma

These were mainly warm up tasks to help familiarise the respondent with the descriptive system.

- 3. Ranking task of 7 intermediate AQLQ health states, full health (AQL-5D health state 11111), worst health state defined by the AQL-5D ('pits' state 55555) and immediate death. Again, this was being used a warm up tasks to help respondent understand the notion of the relative preference for different health states
- 4. TTO valuation of the 7 intermediate AQL-5D health states and 'pits'. The upper anchor of the TTO exercise is 11111.
- 5. Questions on respondent background characteristics

2.2 Modelling health state values

2.2.1 The main models

The overall aim of modelling is to predict values for all health states described by the AQL-5D. The data from these types of valuation surveys are typically skewed and are truncated at one. Furthermore, they will be clustered by respondent as respondents did not value the same set of states. Although the allocation of states to respondents was essentially random, differences between health state values may be partly due to differences in the preferences of the respondents, rather than the dimensions of those states.

A number of alternative models were explored for predicting the TTO scores generated in the valuation survey (taken from Brazier et al, 2002). The general model is:

$$y_{ij} = g(\beta x_{ij} + \theta r_{ij} + \delta r_{ij}) + \varepsilon_{ij}$$
(1)

where i=1,2,...,n represents individual health state values and j=1,2,...,m represents respondents. The dependent variable, y_{ij} , is the TTO score for health state i valued by respondent j. x is a vector of binary dummy variables $(x_{\delta i})$ for each level λ of dimension δ of the classification. Level $\lambda=1$ acts as the baseline for each dimension. z is a vector of personal characteristics, which is examined in terms of respondent's gender, age and asthma condition in this paper. The r term is a vector of terms to account for interactions, which are examined in terms of interactions between the levels of different dimensions. g is a function specifying the appropriate functional form. ε_{ij} is an error term whose autocorrelation structure and distributional properties depend on the assumptions underlying the particular model used.

The starting point is individual level models treating each observation as an independent value. The first approach is an OLS estimation of model (1), with g as a linear. Possible improved specifications, which take account of variation both within and between respondents, are the one-way error components random effects model and fixed-effects model. Hausman's test is used to make a choice between those two specifications.

Estimation is via generalized least squares (GLS) or maximum likelihood estimation (MLE). The second approach is at the aggregate level, and aggregate level models are estimated based on the mean TTO value of each health state using OLS estimation. For this approach, the j subscript and the z vector are dropped from equation (1) above. The third approach is the inclusion of interaction terms. There is evidence that preferences for different dimensions of health may not be additive. Therefore it is important to try to estimate interactions. Adapting the approach used in other studies (Brazier et al. 2002), an

interaction variable C3_2 was created as a dummy variable which takes a value of 1 if two or more dimensions in the health state are at level 4 or 5, and 0 otherwise.

To avoid negative values, all models were estimated using a dependent variable defined as dis_tto (1- TTO). Given 1 denotes full health; this variable dis_TTO indicates the extent to which a given health state moves away from full health. Thus, the more sever the ill health state, the greater the coefficient should be, and the expected signs of the dummy coefficients should be positive.

Given the fact that we used AQL-5D full health 11111 as our upper anchor for TTO, the choice of the best model should be between models without a constant term¹. This is due to the fact that we do not have AQL-5D 11111 valued against some generic full health such as "no health problems at all". If AQL-5D 11111 had been valued against generic full health, then AQL-5D 11111 can be represented by the intercept term and the best model can be selected using the with-constant model. Thus the choice of the best model is based on theoretical concerns, rather than the empirical performance though other performance criteria are helpful. For instance, models

were compared (where available) in terms of their overall diagnosis by adjusted R squared, goodness of fit, likelihood ratio, the size and significance of individual parameter estimates,

¹ When models are estimated using dis_TTO as dependent variable, the choice of model should be between models without constant. This is equivalent to models estimated using TTO as dependent variable, where constants are forced to be 1 as full health.

as well as their predictive ability by mean absolute errors (MAE) and T-test between observed and predicted values and the numbers of errors greater than 0.05 and 0.10 in absolute value. Plots was used to illustrate possible pattern of predict errors. Treating health state values as time series data sorting by observed values, Ljung-box test was used to test autocorrelation in the prediction errors of models observed mean health state values.

All modelling was carried out using STATA 9.0 and SPSS 12.0 for Windows.

2.2.2 The effect of respondent characteristics

In order to explore the effect of basic respondent characteristics, age and gender were included in the OLS model identified above. The reason to choose the OLS model was that it performed better in terms of predictive ability compared with the Random Effects model although both of them were estimated at individual level. Age was represented as six groups ranging from the 18 to 25 years old as the baseline up to the over 66 group (see table 3), gender was represented by a male dummy.

In addition, it was noted at the pilot stage that a significant proportion of respondents reported having experience of asthma themselves (17.2%). Therefore, an additional analyse was included in the main survey, to explore the effect of the respondents' experience of asthma. This was explored by adding a dummy representing whether or not the respondent has asthma to the OLS model, with 'having asthma' as the baseline. The sign and the significance of this asthma dummy itself, and the extent to which the other coefficients were affected by its inclusion were the focus of interest.

3. Results

3.1 Main valuation survey

3.1.1 Respondents

A sample of 307 members of the general population (response rate 40%) from South Yorkshire was interviewed. They were all included in the final dataset for analysis. This sample was proved to be a representative sample of the UK general population in terms of age and gender. The description of the sample is shown in Table 3. Among the respondents, more than half are female, between 36 to 65 years old, married or living with partner, and experienced serious illness in their family. In this sample, 17.3% have asthma, 22.5% respondents have a degree or equivalent, and 45.6% respondents received full-time education after 17. The self-reported EQ-5D scores of the respondents by sex are also shown in table 3, which are slightly lower than the UK population norms with 0.86 for males and 0.85 for females.

3.1.2 Health state values

In all there were 2455 health state valuations generated by the respondents. Average number of valuations per intermediate health state was 22 (range from 19 to 22) where as the 'pits' state (AQL-5D state 55555) was valued 307 times, by every respondent. The mean health state values ranged from 0.39 to 0.94 and generally have fairly large standard deviations (around 0.2 to 0.4). The distribution of the values was negatively skewed. Table 4 presents health valuation values in blocks 1 to 7 as examples (results of remaining states are available from the corresponding author on request).

3.2 Modelling

3.2.1 The main regression results

The results of modelling are presented in Table 5, with summary statistics for internal sample predictions presented in the lower half of the table. Models (1) to (4) were estimated at the individual level while models (5) to (7) were mean models estimated at the aggregate level. Models were estimated on the basis of the main effects dummies except those with the interaction variable C3_2. A fixed effects model was not present here as Hausman's test suggested random effects rather than fixed effects model.

For theoretical reasons, 'the best model' should be chosen between models that exclude the constant term. Thus all models were estimated without constant terms. Among those models estimated, individual level models (1) and (2) have no inconsistencies within significant coefficients, whereas mean model (5) has 2. The number of significant coefficients among models is comparable (range from 13 to 15). Given different observation basis, the adjusted R² values between individual models and mean models are not comparable with each other. In terms of prediction ability, model (1) and model (5) performed equally well with comparable MAE (0.048 vs. 0.047), numbers of absolute residuals larger than 0.05 (39 vs. 35) and 0.10 (6 vs. 9), while model (3) performed worse than them with larger MAE (0.057), more residuals larger than 0.05 (42) and 0.10 (19). Ljung-Box test has been used to test autocorrelation between errors. The results showed that there were no significant autocorrelation between errors in models (1), (3) and (5).

Introduction of interaction term C3_2 in the main effects models resulted in models (2), (4) and (7). The coefficients for C3_2 term were non-significant for models (2) and (7), while significant for model (4) with a negative sign. However, inclusion of C3_2 did not result in appreciable change to the size of the main effects coefficients, nor any improvement of prediction ability. In fact, the residual T-test for models (2) and (3), and the LB test for model (4) became significant while main effects model were non-significant. Thus, the interaction term C3_2 was not to be included in the final model.

Given the main purpose of modelling is to predict mean TTO values of all possible health states defined by AQL-5D based on the valuation survey, the predictive ability of models was used as the main criteria for model comparison and selection. As a result, the choice of model is between model (1) (OLS model) and model (5) (Mean model), which have equally good predictive ability. The mean model (5) is chosen as the best model, because health state values required in economic evaluation are the average values of specific health states, which means the aggregate level rather than the individual level. However, model (5) has 3 inconsistent coefficients - between breath level 1 as baseline and level 2, between breath levels 4 and 5, and between activity levels 4 and 5, so these inconsistent levels were merged to improve coefficient consistency, which resulted in model (6). Model (6) is the final recommended model for use in future economic evaluations.

3.2.2 The additional analyses

Table 6 presents the OLS models before (model (1)) and after (model (8)) covariates (having asthma, gender and age) were introduced. While comparing the two models, the

adjusted R square did not change remarkably after including covariates (0.522 vs. 0.535). Most main effects coefficients showed very minor change at 0.001 level while the coefficients within sleep dimension seemed to be most affected.

In model (8), the coefficient for not having asthma is 0.045 (p < 0.05). This indicates that asthma patients have lower dis_TTO values than the general public, which means they are on average giving higher values to asthma states. The coefficient for gender is 0.048 (p<0.05). This indicates that females have higher dis_TTO values than males, which means they are on average giving lower values to health states. These two coefficients were similar in size which may indicates that asthma condition and gender have similar effects on the model. Further, the coefficients for age groups ranged from -0.118 to 0.020, with groups 26 to 35 and 46 to 55 had negative values and were significant at 0.05 level, which indicates that those two age groups in general gave higher values to health states. The coefficients of other age groups were non-significant at 0.05 level.

4. Discussion and conclusion

This paper presents a study to estimate a preference-based single index from a condition specific quality of life instrument, using the AQLQ. This means that it is possible to convert AQLQ data sets into health state utility values for use in economic evaluations. The alleged advantage of condition specific preference-based measures over generic ones is that they use a descriptive system that is more relevant and sensitive to the condition. However, concerns have been expressed in the literature about the appropriateness of

condition specific measures for use in making cross programme comparison (Brazier et al, 2007)

A related issue is the choice of condition specific full health (AQL-5D state 11111) as opposed to generic "full health" as the upper anchor for TTO valuation. Given that it is quite possible to conceive of health states that involve no respiratory problems (and hence correspond to AQL-5D 11111), and yet involve other health problems (e.g. pain), an alternative design would be to use a generic description such as "no health problems" as the upper TTO anchor and to directly evaluate AQL-5D 11111 against this and death. The difficulty with this is that since the other dimensions of health are not explicitly mentioned, it could be confusing to respondents.

We do not know what respondents were thinking during the interview: did they only think about the condition as described by AQL-5D, or did they extend their imagination to other aspects of health not included by in the descriptive system, such as depression or pain. Respondents might imagine that other dimensions are either at their best level, or some level constant between AQL-5D states (such as their current health), then provided there are no interactions between those states that are included in the AQL-5D and those dimensions excluded from its descriptive system, then this should not matter. However, there is a good chance that there are interactions between these dimensions, and without further data we can not know how important these are likely to be. In addition, if the levels given to these other dimensions of health were related to the main asthma specific dimensions of health (e.g. no pain and not depressed for the mild asthma states, but severe

pain and very depressed for the severe asthma states), then this would also have implications for the final health state values

On more specific design issues, the selection of the health state sample for valuation and modelling was based on balanced design regardless of the prevalence of health state in population, which may cause difficulty for respondents to imagine those health states happened rarely in real life. We checked the feasibility of the states and none seemed to cause any problems for respondents. Further, the sample size of over 300 might be thought to be small compared the original EQ-5D valuation survey with a sample of 3000, given the AQL-5D descriptive system defines 13 times more health states than the EQ-5D. We were limited by resource constraints since the collection of stated preference data by interview is expensive. However, in terms of MAE, the results are both around 0.05 and the chosen model did not suffer from many inconsistencies. A larger sample size with more states may have allowed us to estimate significant interaction terms, but the additive model seemed to perform satisfactorily against conventional statistical tests

The additional regression analyses introduce covariance of gender, age and asthma condition into the OLS model. Although the coefficients of the main effects variables mainly remain unchanged, the gender variable is statistically significant. Two age groups are also significantly different from the reference age group (18 to 25), which indicates that older people of specific age group were giving higher values. Nevertheless, these results imply potential influence of respondents' personal characteristics.

The impact of patients' asthma condition to health state valuation has also been examined by using a variable to represent whether or not the respondent has asthma in the OLS models. This resulted in the coefficients being significant and being positive in the model. This indicates that there was statistically significant difference between the way respondents with and without asthma valued the hypothetical asthma states. Further, respondents with asthma valued the hypothetical asthma states higher than those without asthma, which has been confirmed by findings elsewhere (e.g. Dolan and Roberts, 2004). The possible explanation may be that asthma patients have adapted the condition although they know better of the condition than non-patients. These findings are similar to paper on EQ-5D and SF-6D found gender, age and health status did have significant impact though usually quite modest compared to the descriptive system. (Dolan and Roberts, Kharoubi et al, 2007)

Given people with asthma gave different values; this does raise of the question of the extent to which the general public understood the impact of the condition as discussed below.

Since the preference indices for a specific medical condition was valued by members of the general public, one concern is the extent to which the majority of respondents who have no direct experience of asthma managed to understand and to imagine what it is like to live with asthma.

For informing resource allocation purposes, most agencies require values from a representative population and so this is not relevant. However, we did undertake a pilot study to examine the impact of two ways of explaining the condition to people and found it

had no effect. However, this study found that asthma condition does have an impact on the final results.

In conclusion, this paper is one of the first to present the results from a study to derive a condition-specific preference-based measure from an existing measure of health related quality of life. While the study has been a technical success, it does raise some important policy issues about the use of preference-based condition specific measures compared to generic measures and the role of covariates.

References

Anderson JP, Kaplan RM, Berry CC, et al. Interday reliability of function assessment for a health-status measure - the Quality of Well-being Scale. Medical care 1989; 27 (11): 1076 -1084.

Brazier J, Roberts J, Deverill M. The estimation of a utility based algorithm from the SF-36 Health Survey. Journal of Health Economics 2002: 21:271-292.

Brazier JE, Czoski-Murray C, Roberts J, Brown M, Symonds T, Kelleher C. Estimation of a preference-based index from a condition specific measure: the King's Health Questionnaire. Medical Decision Making (2007, in press)

Brazier JE, Ratcliffe J, Tsuchiya A, Solomon J. Measuring and valuing health for economic evaluation. Oxford: Oxford University Press 2007.

Dolan P. Modelling valuation for Eurogol health states. Medical Care 1997;35:351-363.

Dolan P, Gudex C, Kind P. Valuing health states: A comparison of methods. Journal of Health Economics. 1996:2:209-232.

Dowie J. Decision validity should determine whether a generic or condition-specific HRQOL measure is used in health care decisions. Health Economics 2002; 11:1-8.

Eccles M, Grimshaw J, Steen N, Parkin D, Purves I, McColl E, et al. The design and analysis of a randomized controlled trial to evaluate computerized decision support in primary care: the COGENT study. Family Practice 2000;17(2):180-186

Gudex C. Time Trade-Off User Manual: Props and Self-Completion Methods. Centre for Health Economics, 1994

Juniper EF, Guyatt GH, Ferrie PJ, Griffith LE. Measuring quality of life in asthma. American Review of Respiratory Disease 1993; 147: 832 - 838.

Juniper EF, Buist AS, Cox FM, Ferrie PJ, King DR. Validation of a standardized version of the Asthma Quality of Life Questionnaire. Chest 1999;115(5):1265-1270.

Revicki DA, Leidy NK, et al. Development and preliminary validation of the multiattibute Rhinitis Symptom Utility Index. Quality of life research 1998; 7: 693-702.

Revicki DA, Leidy NK, et al. Intergrating patient preferences into health outcomes assessment: the multiattribute Asthma Symptom Utility Index. Chest 1998; 114:998-1007.

Roberts J, Dolan P. To what extent do people prefer health states with higher values? A note on evidence from the EQ-5D valuation set. Health Economics 2004; 13(7):733-737.

Stolk EA, Busschbach JJV. Validity and feasibility of the use of condition-specific outcome measures in economic evaluation. Quality of life reseach 2003 (12): 363 - 371.

Torrance EA, Kereseci MA, et al. Development and initial validation of a new preference-based disease-spedific health related quality of life instrument form erectile function. Quality of life research 2004; 13:349-359.

Young T, Yang Y, Brazier J, Tsuchiya A. Using Rasch analysis to aid the construction of preference based measures from existing quality of life instruments. Paper presented at the Health Economists' Study Group meeting, Newcastle, summer 2005

Table 1: Standardized AOLO items (taken from Juniper, 1993)

Table 1: Standardized AQLQ items (taken from Juniper, 1993)						
Item No.	Question (during the last 2 weeks) as a result of your asthma	Domain	Wording			
1	Limited strenuous activities	Activity	Limitations			
2	Limited moderate activities	Activity	Limitations			
3	Limited social activities	Activity	Limitations			
4	Limited work-related activities	Activity	Limitations			
5	Limited sleeping	Activity	Limitations			
6	How much discomfort or distress as a result of chest tightness	Symptoms	Quantity			
7	Feel concerned about having asthma	Emotional	Time			
8	Feel short of breath as a result of your asthma	Symptoms	Time			
9	Experience asthma symptoms as a result of being exposed to cigarette smoke	Environment	Time			
10	Experience a wheeze in your chest	Symptoms	Time			
11	Feel you had to avoid a situation or environment because of cigarette smoke	Activity	Time			
12	How much discomfort or distress have you felt as a result of coughing	Symptoms	Quantity			
13	Feel frustrated as a result of your asthma	Emotional	Time			
14	Experience a feeling of chest heaviness	Symptoms	Time			
15	Feel concerned about the need to use medication for your asthma	Emotional	Time			
16	Feel the need to clear your throat	Symptoms	Time			
17	Experience asthma symptoms as a result of being exposed to dust	Environment	Time			
18	Experience difficulty breathing out as a result of your asthma	Symptoms	Time			
19	Feel you had to avoid a situation or environment because of dust	Activity	Time			
20	Wake up in the morning with asthma symptoms	Symptoms	Time			
21	Feel afraid of not having your asthma medication available	Emotional	Time			
22	Feel bothered by heavy breathing	Symptoms	Time			
23	Experience asthma symptoms as a result of the weather or air pollution outside	Environment	Time			
24	Were you woken at night by your asthma	Symptoms	Time			
25	Avoid or limit going outside because of the weather or air pollution	Activity	Time			
26	Experience asthma symptoms as a result of being exposed to strong smells or perfume	Environment	Time			
27	Feel afraid of getting out of breath	Emotional	Time			
28	Feel you had to avoid a situation of environment because of strong smells or perfume	Activity	Time			
29	Has your asthma interfered with a good night's sleep	Symptoms	Time			
30	Have a feeling of fighting for air	Symptoms	Time			
31	How much has your range of activities you would like to have done been limited by your asthma	Activity	Limitations			
32	Among all the activities you have done how limited have you been by your asthma	Activity	Limitations			

Table 2 the reduced asthma quality of life classification (AQL-5D)

CONCERN

- 1. Feel concerned about having asthma none of the time.
- 2. Feel concerned about having asthma a little or hardly any of the time.
- 3. Feel concerned about having asthma some of the time.
- 4. Feel concerned about having asthma most of the time.
- 5. Feel concerned about having asthma all of the time.

SHORT OF BREATH

- 1. Feel short of breath as a result of asthma none of the time.
- 2. Feel short of breath as a result of asthma a little or hardly any of the time.
- 3. Feel short of breath as a result of asthma some of the time.
- 4. Feel short of breath as a result of asthma most of the time.
- 5. Feel short of breath as a result of asthma all of the time.

WEATHER & POLLUTION

- 1. Experience asthma symptoms as a result of air pollution none of the time.
- 2. Experience asthma symptoms as a result of air pollution a little or hardly any of the time.
- 3. Experience asthma symptoms as a result of air pollution some of the time.
- 4. Experience asthma symptoms as a result of air pollution most of the time.
- 5. Experience asthma symptoms as a result of air pollution all of the time.

SLEEP

- 1. Asthma interferes with getting a good night's sleep none of the time.
- 2. Asthma interferes with getting a good night's sleep a little or hardly any of the time.
- 3. Asthma interferes with getting a good night's sleep some of the time.
- 4. Asthma interferes with getting a good night's sleep most of the time.
- 5. Asthma interferes with getting a good night's sleep all of the time.

ACTIVITIES

- 1. Overall, not at all limited with all the activities done.
- 2. Overall, a little limitation with all the activities done.
- 3. Overall, moderate or some limitation with all the activities done.
- 4. Overall, extremely or very limited with all the activities done.
- 5. Overall, totally limited with all the activities done.

Table 3 Characteristics of respondents in evaluation survey (N=307)

	Count	Percentage
Age		
18-	34	11.1
26-	57	18.6
36-	61	19.9
46-	50	16.3
56-	45	14.7
66-	60	19.5
Female	168	54.7
Have asthma	53	17.3
Married or living with partner	214	69.8
Experienced serious illness:		
in family	194	63.4
themselves	94	30.6
Degree or equivalent	69	22.5
Education after 17	140	45.6
Renting property	64	20.8
Found valuation task difficult:		
very difficult	24	7.9
quite difficult	82	26.7
Neither difficult nor easy	52	16.9
Self-reported EQ-5D score	male	female
Respondent sample	0.83	0.84
UK population	0.85	0.86

Table 4 Descriptive statistics for AQL-5D health state values (blocks 1 to 14)

c bloc N Mean Std. Deviation Median Minimum 15311 1 21 0.763 0.239 0.800 0.375 25313 1 21 0.783 0.206 0.825 0.375 32235 1 21 0.793 0.221 0.825 0.375 41322 1 21 0.861 0.173 0.925 0.525 42245 1 21 0.708 0.322 0.825 -0.275 42325 1 21 0.792 0.221 0.825 0.300 54245 1 21 0.648 0.311 0.700 -0.225 23235 2 23 0.747 0.213 0.825 0.375 25112 2 23 0.768 0.183 0.800 0.500 33132 2 23 0.738 0.218 0.800 0.325 42214 2 23 0.705 0.265 0	Maximum 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
25313 1 21 0.783 0.206 0.825 0.375 32235 1 21 0.793 0.221 0.825 0.375 41322 1 21 0.861 0.173 0.925 0.525 42245 1 21 0.708 0.322 0.825 -0.275 42325 1 21 0.792 0.221 0.825 0.300 54245 1 21 0.648 0.311 0.700 -0.225 23235 2 23 0.747 0.213 0.825 0.375 25112 2 23 0.768 0.183 0.800 0.500 33132 2 23 0.861 0.178 0.925 0.375 42214 2 23 0.738 0.218 0.800 0.325 43234 2 23 0.705 0.265 0.725 0.075	1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
32235 1 21 0.793 0.221 0.825 0.375 41322 1 21 0.861 0.173 0.925 0.525 42245 1 21 0.708 0.322 0.825 -0.275 42325 1 21 0.792 0.221 0.825 0.300 54245 1 21 0.648 0.311 0.700 -0.225 23235 2 23 0.747 0.213 0.825 0.375 25112 2 23 0.768 0.183 0.800 0.500 33132 2 23 0.861 0.178 0.925 0.375 42214 2 23 0.738 0.218 0.800 0.325 43234 2 23 0.705 0.265 0.725 0.075	1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
41322 1 21 0.861 0.173 0.925 0.525 42245 1 21 0.708 0.322 0.825 -0.275 42325 1 21 0.792 0.221 0.825 0.300 54245 1 21 0.648 0.311 0.700 -0.225 23235 2 23 0.747 0.213 0.825 0.375 25112 2 23 0.768 0.183 0.800 0.500 33132 2 23 0.861 0.178 0.925 0.375 42214 2 23 0.738 0.218 0.800 0.325 43234 2 23 0.705 0.265 0.725 0.075	1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
42245 1 21 0.708 0.322 0.825 -0.275 42325 1 21 0.792 0.221 0.825 0.300 54245 1 21 0.648 0.311 0.700 -0.225 23235 2 23 0.747 0.213 0.825 0.375 25112 2 23 0.768 0.183 0.800 0.500 33132 2 23 0.861 0.178 0.925 0.375 42214 2 23 0.738 0.218 0.800 0.325 43234 2 23 0.705 0.265 0.725 0.075	1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
42325 1 21 0.792 0.221 0.825 0.300 54245 1 21 0.648 0.311 0.700 -0.225 23235 2 23 0.747 0.213 0.825 0.375 25112 2 23 0.768 0.183 0.800 0.500 33132 2 23 0.861 0.178 0.925 0.375 42214 2 23 0.738 0.218 0.800 0.325 43234 2 23 0.705 0.265 0.725 0.075	1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
42325 1 21 0.792 0.221 0.825 0.300 54245 1 21 0.648 0.311 0.700 -0.225 23235 2 23 0.747 0.213 0.825 0.375 25112 2 23 0.768 0.183 0.800 0.500 33132 2 23 0.861 0.178 0.925 0.375 42214 2 23 0.738 0.218 0.800 0.325 43234 2 23 0.705 0.265 0.725 0.075	1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
54245 1 21 0.648 0.311 0.700 -0.225 23235 2 23 0.747 0.213 0.825 0.375 25112 2 23 0.768 0.183 0.800 0.500 33132 2 23 0.861 0.178 0.925 0.375 42214 2 23 0.738 0.218 0.800 0.325 43234 2 23 0.705 0.265 0.725 0.075	1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
23235 2 23 0.747 0.213 0.825 0.375 25112 2 23 0.768 0.183 0.800 0.500 33132 2 23 0.861 0.178 0.925 0.375 42214 2 23 0.738 0.218 0.800 0.325 43234 2 23 0.705 0.265 0.725 0.075	1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
25112 2 23 0.768 0.183 0.800 0.500 33132 2 23 0.861 0.178 0.925 0.375 42214 2 23 0.738 0.218 0.800 0.325 43234 2 23 0.705 0.265 0.725 0.075	1.000 1.000 1.000 1.000 1.000 1.000 1.000
42214 2 23 0.738 0.218 0.800 0.325 43234 2 23 0.705 0.265 0.725 0.075	1.000 1.000 1.000 1.000 1.000 1.000 1.000
42214 2 23 0.738 0.218 0.800 0.325 43234 2 23 0.705 0.265 0.725 0.075	1.000 1.000 1.000 1.000 1.000 1.000
43234 2 23 0.705 0.265 0.725 0.075 51454 2 23 0.588 0.391 0.700 -0.375 54333 2 23 0.715 0.225 0.775 0.375	1.000 1.000 1.000 1.000 1.000
51454 2 23 0.588 0.391 0.700 -0.375 54333 2 23 0.715 0.225 0.775 0.375	1.000 1.000 1.000 1.000
54333 2 23 0.715 0.225 0.775 0.375	1.000 1.000 1.000
	1.000 1.000
15131 3 19 0.785 0.218 0.825 0.375	1.000
24422 3 19 0.720 0.299 0.825 0.000	
31155 3 19 0.582 0.376 0.675 -0.300	1.000
31531 3 19 0.726 0.334 0.925 0.000	1.000
32435 3 19 0.688 0.288 0.750 0.000	1.000
32435 3 19 0.688 0.288 0.750 0.000 34554 3 19 0.488 0.413 0.475 -0.450	1.000
42542 3 19 0.708 0.294 0.825 0.000	1.000
13251 4 23 0.843 0.252 0.950 0.000	1.000
15251 4 23 0.814 0.259 0.994 0.000	1.000
15355 4 23 0.597 0.477 0.725 -0.950	1.000
25425 4 23 0.578 0.485 0.675 -0.975	1.000
41211 4 23 0.872 0.201 1.000 0.500	1.000
41442 4 23 0.825 0.271 0.992 0.000	1.000
51451 4 23 0.767 0.311 0.925 0.000	1.000
12144 5 25 0.706 0.280 0.775 0.025	1.000
14225 5 25 0.756 0.255 0.825 0.000	1.000
21223 5 25 0.814 0.271 0.925 0.000 35422 5 25 0.748 0.225 0.875 0.350	1.000
35422 5 25 0.748 0.225 0.875 0.350	1.000
45553 5 25 0.584 0.498 0.675 -0.950	1.000
51522 5 25 0.818 0.249 0.925 0.175	1.000
53532 5 25 0.737 0.416 0.925 -0.950	1.000
12314 6 21 0.665 0.426 0.825 -0.775	1.000
24133 6 21 0.698 0.238 0.625 0.375	1.000
34254 6 21 0.473 0.426 0.500 -0.500	1.000
34351 6 21 0.671 0.373 0.775 -0.475	1.000
45532 6 21 0.640 0.516 0.875 -0.725	1.000
51214 6 21 0.673 0.384 0.825 -0.375	1.000
54123 6 21 0.738 0.337 0.875 -0.475	1.000
12543 7 24 0.745 0.247 0.725 0.025	1.000
13321 7 24 0.845 0.239 0.950 0.025	1.000
25421 7 24 0.790 0.263 0.900 0.000	1.000
25543 7 24 0.631 0.335 0.713 -0.275	1.000
32412 7 24 0.841 0.172 0.912 0.500	1.000
44135 7 24 0.613 0.365 0.650 -0.375	1.000
53242 7 24 0.748 0.221 0.738 0.025	1.000
11233 8 21 0.836 0.205 0.925 0.275	1.000
14341 8 21 0.730 0.243 0.800 0.125	1.000

•							,
14444	8	21	0.529	0.451	0.575	-0.875	1.000
23154	8	21	0.714	0.276	0.800	0.000	1.000
33323	8	21	0.818	0.227	0.900	0.275	1.000
42554	8	21	0.571	0.457	0.725	-0.825	1.000
54152	8	21	0.701	0.382	0.875	-0.500	1.000
21332	9	19	0.850	0.221	0.925	0.400	1.000
22242	9	19	0.801	0.237	0.900	0.225	1.000
24433	9	19	0.715	0.305	0.825	0.025	1.000
32441	9	19	0.833	0.256	0.925	0.075	1.000
44114	9	19	0.562	0.513	0.725	-0.950	1.000
45143	9	19	0.704	0.301	0.725	0.025	1.000
45253	9	19	0.764	0.301	0.725	-0.775	1.000
	9 10	25					1.000
13431			0.798	0.228	0.900	0.200	
21113	10	25	0.885	0.133	0.925	0.450	1.000
23534	10	25	0.633	0.286	0.625	0.000	1.000
41125	10	25	0.685	0.248	0.725	0.000	1.000
41153	10	25	0.733	0.308	0.800	-0.400	1.000
53325	10	25	0.540	0.381	0.575	-0.300	1.000
53525	10	25	0.467	0.419	0.500	-0.700	1.000
13514	11	23	0.691	0.265	0.700	0.125	1.000
24335	11	23	0.629	0.278	0.650	0.000	1.000
31143	11	23	0.805	0.201	0.875	0.325	1.000
41112	11	23	0.891	0.164	0.950	0.425	1.000
45341	11	23	0.769	0.273	0.875	0.075	1.000
52444	11	23	0.699	0.214	0.700	0.300	1.000
53411	11	23	0.827	0.192	0.925	0.375	1.000
23312	12	21	0.937	0.105	1.000	0.600	1.000
24352	12	21	0.875	0.175	0.925	0.325	1.000
33511	12	21	0.900	0.135	1.000	0.500	1.000
33552	12	21	0.849	0.194	0.925	0.300	1.000
52112	12	21	0.934	0.127	1.000	0.525	1.000
52314	12	21	0.855	0.201	0.925	0.325	1.000
55424	12	21	0.780	0.220	0.825	0.375	1.000
13434	13	20	0.586	0.407	0.700	-0.575	1.000
15331	13	20	0.830	0.166	0.825	0.525	1.000
24524	13	20	0.486	0.500	0.563	-0.575	1.000
35453	13	20	0.614	0.387	0.625	-0.375	1.000
41123	13	20	0.805	0.313	0.912	-0.425	1.000
52141	13	20	0.840	0.313	0.963	-0.423 -0.375	1.000
55521	13	20	0.578	0.459	0.688	-0.475	1.000
11445	14	22	0.696	0.235	0.713	0.225	1.000
12511	14	22	0.819	0.228	0.938	0.375	1.000
15553	14	22	0.701	0.376	0.800	-0.475	1.000
31215	14	22	0.712	0.257	0.763	0.225	1.000
32414	14	22	0.672	0.357	0.787	-0.400	1.000
33245	14	22	0.717	0.264	0.750	0.225	1.000
34225	14	22	0.641	0.367	0.675	-0.475	1.000
55555	1~14	307	0.390	0.450	0.425	-0.975	1.000

Main models Estimated Table 5

Individual models						Mean models		
Dimension	OLS	OLS+C3_2	RE	RE+C3_2	mean	Mean1	mean+C3_2	
levels	(1)	(2)	(3)	(4)	(5)	(6)	(7)	
_lconcern_2	0.028	0.027	0.028	0.029	0.027	0.027	0.027	
_lconcern_3	0.045	0.044	0.044	0.045	0.047	0.046	0.046	
_lconcern_4	0.062	0.076	0.054	0.073	0.064	0.064	0.073	
_lconcern_5	0.077	0.087	0.081	0.096	0.064	0.064	0.074	
lbreath 2	-0.004	-0.002	0.001	0.006	-0.003		-0.001	
_lbreath_3	0.027	0.034	0.037	0.046	0.028	0.030	0.032	
_lbreath_4	0.102	0.122	0.102	0.126	0.107	0.030	0.12	
_lbreath_5	0.102	0.119	0.102	0.128	0.107	0.106	0.111	
0	• • • • • • • • • • • • • • • • • • • •	011.10	• • • • • • • • • • • • • • • • • • • •	020	01.01	0.100	0	
_lpollutio~2	0.009	0.008	0.019	0.018	0.015	0.013	0.013	
_lpollutio~3	0.027	0.027	0.05	0.053	0.029	0.028	0.028	
_lpollutio~4	0.055	0.069	0.058	0.074	0.057	0.058	0.067	
_lpollutio~5	0.12	0.127	0.121	0.128	0.112	0.113	0.12	
_lsleep_2	0.036	0.046	-0.018	-0.01	0.044	0.041	0.049	
_lsleep_3	0.053	0.055	-0.009	-0.01	0.058	0.056	0.059	
_lsleep_4	0.071	0.091	0.033	0.057	0.076	0.073	0.089	
_lsleep_5	0.097	0.113	0.055	0.074	0.091	0.090	0.104	
_lactivity_2	0.01	0.01	0.04	0.038	0.011	0.011	0.01	
_lactivity_3	0.064	0.064	0.06	0.06	0.064	0.065	0.064	
_lactivity_4	0.182	0.197	0.176	0.195	0.183	0.002	0.194	
_lactivity_5	0.187	0.196	0.197	0.206	0.17	0.177	0.18	
C3_2	n/a	-0.044	n/a	-0.052	n/a	0.177	-0.031	
N	2456	2456	2456	2456	99	99	99	
Inconsistencies	0	1	0	NA	2	0	2	
Significant coefficients	13	14	15	15	13	11	14	
R2	0.522	0.522	n/a	n/a	0.948	0.957	0.948	
MAE	0.048	0.046	0.057	0.055	0.047	0.048	0.046	
N>= 0.05	39	32	42	44	35	32	31	
N>= 0.10	6	10	19	15	9	9	9	
T(mean = 0)	0.483	0.528	3.920	0.036	b	b	b	
LB	4.072	5.513	14.206	21.270	5.313	5.768	6.149	

All models used dis_tto as dependent variable. All models were estimated without constant Estimates shown in bold are significant at $P_{0.05}$ $C_{3\cdot 2}$ is an interaction term with 1 denoting two or more dimensions in a health states greater than level 4, 0 otherwise. Inconsistency: count for significant coefficients

b: Mean error is zero by definition

Table 6 OLS model with covariates

-	0	LS	
	(1)	(8)	
_lconcern_2	0.028	0.019	
_lconcern_3	0.045	0.038	
_lconcern_4	0.062	0.051	
_lconcern_5	0.077	0.074	
_lbreath_2	-0.004	-0.010	
_lbreath_3	0.027	0.022	
_lbreath_4	0.102	0.098	
_lbreath_5	0.111	0.105	
_lpollutio~2	0.009	-0.000	
_lpollutio~3	0.027	0.020	
_lpollutio~4	0.055	0.041	
_lpollutio~5	0.12	0.114	
_lsleep_2	0.036	0.032	
_lsleep_3	0.053	0.046	
_lsleep_4	0.071	0.060	
_lsleep_5	0.097	0.087	
_lactivity_2	0.01	0.009	
_lactivity_3	0.064	0.066	
_lactivity_4	0.182	0.185	
_lactivity_5	0.187	0.189	
Non- asthma	-	0.045	
female	-	0.048	
26-	=	-0.118	
36-	=	-0.037	
46-	-	-0.076	
56-	=	0.000	
66-	-	0.020	
N	2456	2448	
Adjusted R2	0.522	0.535	

All models used dis_tto as dependent variable. All models were estimated without constant Estimates shown in bold are significant at $P_{0.05}$

N: observation number

Appendix 1: the information on asthma shown to respondents

What is asthma?

Asthma is a condition that affects the airways - the small tubes that carry air in and out of the lungs. If you have asthma your airways are almost always sensitive and inflamed.

When you come in to contact with something you are allergic to, or something that irritates your airways (a trigger), you airways will become narrower, making it harder to breathe. The muscles around the walls of your airways tighten. The lining of the airways becomes inflamed and starts to swell and often sticky mucus or phlegm is produced. This will lead to you experiencing asthma symptoms.

Asthma symptoms can vary. You may find that you start to cough or wheeze, get short of breath, or have a tight feeling in your chest. Despite what many people think, wheezing does not always occur. In fact, coughing is the most common asthma symptom.

Asthma can start at any age. Some people get symptoms during childhood which then disappear in later life. Others develop 'late-onset' asthma in adulthood, without ever having had symptoms as a child.

Taken from the British Thoracic Society (BTS) website

Appendix 2:

Estimating a single utility index from the Mini Asthma Quality of Life Questionnaire (MiniAQLQ) using the AQL-5D

The MiniAQLQ has been developed and fully validated by Professor Juniper and her colleagues, who has also developed the Asthma Quality Life Questionnaire (AQLQ), in response to a demand for a shorter, standardized version for large clinical trials and for managed care monitoring (Juniper et al, 1999). This instrument has 15 items and each item has the same 7 severity levels as the original AQLQ. The items are in the same domains as the original AQLQ (5 items for the symptoms domain, 4 items for the activities domain, 3 items for the emotions domain and 3 items for the environment domain). Most items are identical to the corresponding items of the original AQLQ although some items have slightly different wording. The MiniAQLQ has very good reliability, cross-sectional validity, responsiveness and longitudinal validity (Juniper et al, 1999).

Although the AQL-5D was derived from the AQLQ, given the large overlap between the AQLQ and the MiniAQLQ questionnaires, the AQL-5D can also be used to derive utility indices from MiniAQLQ data. Four of the 5 AQL-5D dimensions (concern, short of breath, weather & pollution dimensions) have identical MiniAQLQ items. In terms of the activity limitation dimension, the AQL-5D question (item 32 of AQLQ) asks about limitations in all activities that the respondent has undertaken in the last 2 weeks. While there are 4 items relating to activity limitation in the MiniAQLQ, none of them ask the same question. They ask how asthma limited respondents in the last 2 weeks doing different activities: strenuous activities (item 12), moderate activities (item 13), social activities (item 14) and work-related activities (item 15).

In this appendix, 4 different approaches for specifying a level of the AQL-5D activity dimension based on the MiniAQLQ activities items are compared.

- 1. Average of items 13-15 rounded up;
- 2. Average of item 12-15 rounded up;

- 3. Take item 13 as is;
- 4. Take the worst item from items 13 -15.

Averages are rounded up in approaches 1 and 2 because the AQL-5D algorithm is only applicable to round numbers.

Since item 12 (limited strenuous activity) may not represent the level of a respondent's overall activity limitation, this item was only considered in approach 2. Among these 4 approaches, approach 1 took moderate, social and work-related activity limitation into account and we believe is the most appropriate way to obtain the activity dimension of AQL-5D from the MiniAQLQ. Three other approaches were developed to test the sensitivity of the utility values to different assumptions.

The 4 approaches have been applied to the baseline data of a trial containing MiniAQLQ (Lloyd et al, 2007). Table 1 reports AQL-5D health state values resulting from the 4 approaches. The results show little difference between values which range from 0.787 (approach 4) to 0.802 (approach 1). In terms of distribution of values, the median and 20 percentiles resulting from these 4 approaches are also very close to each other.

Table 1 Description for health state values resulting from 4 approaches

		Approach 1	Approach 2	Approach 3	Approach 4
N		106	106	106	106
Mean		0.802	0.794	0.798	0.787
Median		0.826	0.822	0.822	0.807
Std. Deviation		0.131	0.134	0.130	0.131
Minimum		0.450	0.450	0.450	0.450
Maximum		0.970	0.970	0.970	0.970
Percentiles	20	0.714	0.698	0.698	0.690
	40	0.794	0.790	0.790	0.777
	60	0.863	0.849	0.859	0.836
	80	0.922	0.917	0.921	0.913

Pearson correlation coefficients were calculated for utility values resulting from these 4 approaches (Table 2). Correlation coefficients range from 0.930 to 0.976 and are all

significant at the 0.01 level. The Intra Class Correlation (ICC) analysis across these approaches results in a coefficient as 0.949 and is significant at 0.01 significant level.

Table 2 Correlation coefficients for values resulting from 4 approaches

	Approach 1	Approach 2	Approach 3	Approach 4
Approach 1	1.000			
Approach 2	0.976*	1.000		
Approach 3	0.941*	0.942*	1.000	
Approach 4	0.941*	0.930*	0.974*	1.000

^{*} Correlation is significant at 0.01 level (2 tailed)

The above analysis shows that results from approach 1 and the other approaches were of little difference in terms of mean and median values, as well as distribution of indices. In fact, the results were closely correlated as shown by Pearson and ICC correlation coefficients. Thus, the approach 1 is recommended as a practical solution.

A SPSS syntax file to calculate utility indices from the MiniAQLQ questionnaire based on approach 1 is available from the authors on request.

Reference:

- 1. Juniper EF, Guyatt GH, Cox FM, Ferrie PJ, King DR. Development and validation of the Mini Asthma Quality of Life Questionnaire. European Respiratory Journal 1999; 14: 32-38
- 2. Measurement of Health Related Quality of life: Adult Asthma (http://www.qoltech.co.uk/Asthma1.htm)
- 3. Lloyd A, Price D, Brown R. The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Primary Care Respiratory Journal 2007; 16 (1):22 -27